Fundz

Glaukos Corporation

Aliso Viejo, California, United States · Biotechnology, Health Care, Medical · 871 employees

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that focuses on developing innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company aims to provide novel, non-invasive treatments designed to improve patient comfort and recovery times. Their product, Epioxa™, is part of their iLink therapy line, which utilizes bio-ac

Recent signals

  • Feb 23, 2026: Acquired GLAUKOS Corp acquires Mobius Therapeutics for $12.4M
  • Jan 13, 2026: SEC 8-K (2.02): On January 13, 2026, Glaukos Corporation announced preliminary, unaudited net sales results for the fourth quarter and fiscal year ended December 31, 2025. The release indicates sales details that will provide insights into the company's financial health and performance over the past year, which may impact future investment decisions. This quarter's results are particularly critical as they give stakeholders a view of the company's trajectory and operational efficiency. The specific financial figures will be presented in the associated press release, which serves as a key update for investors and market analysts regarding Glaukos's ongoing business performance.
  • Oct 08, 2025: Launched Glaukos Corporation has launched iDose® TR, a groundbreaking intracameral procedural pharmaceutical for glaucoma treatment.
  • Oct 16, 2024: Launched Glaukos Corporation Launches Epioxa™, a Next-Generation Treatment for Keratoconus with Positive Trial Outcomes.

See plans & pricing → Track Glaukos Corporation’s funding, hiring, and signals — with verified contacts — on Fundz.